A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma

被引：0
|
作者：
Huang, Wendy E. [1 ]
Archer, Christine [1 ]
Yip, Desmond [1 ,2 ]
Kanjanapan, Yada [1 ,2 ]
Peters, Geoffrey [1 ,2 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324
引用
下载
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [1] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H. J.
    Arance, A. M.
    Cowey, C. L.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M. O.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    Gonzalez, R.
    Kudchadkar, R. R.
    Smylie, M.
    Meyer, N.
    Mortier, L.
    Atkins, M. B.
    Long, G. V.
    Bhatia, S.
    Lebbe, C.
    Rutkowski, P.
    Yokota, K.
    Yamazaki, N.
    Kim, T. M.
    de Pril, V.
    Sabater, J.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
  • [2] Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
    Mandala, Mario
    Larkin, James
    Ascierto, Paolo Antonio
    Del Vecchio, Michele
    Gogas, Helen
    Cowey, C. Lance
    Arance, Ana
    Dalle, Stephane
    Schenker, Michael
    Grob, Jean-Jacques
    Chiarion-Sileni, Vanna
    Marquez, Ivan
    Butler, Marcus O.
    Di Giacomo, Anna Maria
    Lutzky, Jose
    De la Cruz-Merino, Luis
    Atkinson, Victoria
    Arenberger, Petr
    Hill, Andrew
    Fecher, Leslie
    Millward, Michael
    Khushalani, Nikhil, I
    de Pril, Veerle
    Lobo, Maurice
    Weber, Jeffrey
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [3] PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
    Eggermont, Alexander M. M.
    Ascierto, Paolo A.
    Khushalani, Nikhil, I
    Schadendorf, Dirk
    Boland, Genevieve
    Weber, Jeffrey
    Lewis, Karl D.
    Johnson, Daniel
    Rivalland, Gareth
    Khattak, Adnan
    Majem, Margarita
    Gogas, Helen
    Long, Georgina, V
    Currie, Sue L.
    Chien, David
    Tagliaferri, Mary A.
    Carlino, Matteo S.
    Diab, Adi
    FUTURE ONCOLOGY, 2022, 18 (08) : 903 - 913
  • [4] Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma
    Sullivan, Ryan Joseph
    LANCET, 2020, 395 (10236): : 1524 - 1525
  • [5] REAL-WORLD OUTCOMES OF PATIENTS WITH RESECTED STAGE IIIA MELANOMA TREATED WITH ADJUVANT NIVOLUMAB
    Samlowski, Wolfram
    Nicholas, Robert
    Poretta, Tayla
    Moshyk, Andriy
    Rajkumar, Jonathan
    Salvatore, Anthony
    Stwalley, Brian
    Nwokeji, Esmond
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A131 - A131
  • [6] Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data
    Moser, Justin C.
    Bhatia, Shailender
    Amin, Asim
    Pavlick, Anna C.
    Betts, Keith A.
    Du, Ella Xiaoyan
    Poretta, Tayla
    Shelley, Karishma
    Srinivasan, Swetha
    Sakkal, Leon Alan
    Palaia, Jennell
    Lobo, Maurice
    Pe Benito, Melanie
    Linton, Joshua A.
    Chen, Yan
    Xu, Churong
    Yin, Lei
    Sundar, Manasvi
    Weber, Jeffrey
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [7] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
    Weber, J.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J-J.
    Sileni, V. Chiarion
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M.
    de la Cruz Merino, L.
    Lobo, M.
    de Pril, V.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S731 - S732
  • [8] Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis
    Hoffmann, Michele
    Hayoz, Stefanie
    Ozdemir, Berna C.
    BIOLOGY-BASEL, 2022, 11 (03):
  • [9] The gut microbiome is associated with recurrence free survival in patients with resected Stage III or Stage IV melanoma treated with immune checkpoint inhibitors
    Usyk, Mykhaylo
    Hayes, Richard B.
    Knight, Rob
    Gonzalez, Antonio
    Li, Huilin
    Osman, Iman
    Weber, Jeffrey S.
    Ahn, Jiyoung
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Management of resected stage III/IV melanoma with adjuvant immunotherapy.
    Johnson, Rebecca
    Atkinson, Victoria
    Bhave, Prachi
    Weppler, Alison Margaret
    Peters, Geoffrey David
    Abed, Afaf
    Lyle, Megan
    Khattak, Muhammad Adnan
    Haydon, Andrew Mark
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Long, Georgina V.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345